Valion Bio, Inc. Stock Split Ratio
Valion Bio, Inc. (VBIO) reported Stock Split Ratio of 5.88% for the 1-month period ending 2025-03-31, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2025-08-14
- 2025-03-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 5.88%.
- 2025-03-07: Stockholders' Equity Note, Stock Split, Conversion Ratio 5.88%.
- 2023-08-23: Stockholders' Equity Note, Stock Split, Conversion Ratio 1.00%.
- 2021-08-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 25.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|---|
| 2025-03-31 | 5.88% 10-Q · filed 2025-08-14 | |
| 2025-03-07 | 5.88% 10-Q · filed 2025-08-14 | |
| 2023-08-23 | 1.00% 10-K · filed 2025-03-21 | |
| 2021-08-31 | 25.00% 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |